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ORIGINAL RESEARCH
Objectives: 1. To determine if there are differences in the classes of antihypertensive agents
prescribed for the elderly population as compared with younger patients. 2. To compare patterns
of antihypertensive therapy with established national guidelines.
Design: National Ambulatory Medical Care Survey (NAMCS) database analysis from 1995–
2000.
Setting: Multiple outpatient clinic settings in the US.
Participants: Primary care and sub-specialty physicians and their patients.
Measurements: 332 510 280 outpatient visits with an ICD-9 code corresponding to a
diagnosis of hypertension were analyzed. The class(es) of antihypertensive medications that
patients were already taking and/or those added in that visit were noted. Demographics of the
patients were also analyzed.
Results: There was a statistically significant association between the prescription of diuretics,
calcium-channel blockers (CCBs), alpha-1-blockers (A1Bs), alpha-2 agonists (A2Ags) and
age ≥65 years.
Conclusion: Patients aged 65 and over were prescribed different types of medications than
those under age 65. Increased usage of diuretics and CCBs were in accordance with evidence-
based guidelines for this group. A1Bs were likely used more due to co-morbid benign prostatic
hyperplasia (BPH), but this is not certain. The increased prescription of A2Ags likely reflects
long-term usage of these medications, which nonetheless may be hazardous due to their
potential for causing increased cognitive dysfunction in the aged.
Keywords: aged, hypertension, therapeutics, drug prescriptions, physician’s practice patterns
Introduction
Hypertension is commonly encountered in the aging population. The third National
Health and Nutrition Examination Survey (NHANES III) found that 65% of
individuals over 60 years of age were hypertensive (Burt et al 1995). An analysis of
the Framingham database revealed that late middle-aged individuals (between ages
55 and 65) have a residual lifetime risk for hypertension of nearly 90% (Vasan et al
2002). Randomized, controlled trial data demonstrate that antihypertensive therapy
reduces morbidity and mortality in the elderly (SHEP 1991; Staessen et al 1997;
Neal et al 2000). Collectively, these observations suggest that a high proportion of
the elderly population will receive antihypertensive therapy.
The means whereby clinicians develop a treatment plan for elderly patients with
hypertension is unknown. The aging process is known to be associated with
physiologic changes which raise blood pressure including increased arterial vessel
stiffness, decreased arterial compliance, reduced beta-adrenergic function, and
decreased plasma renin activity (Weber et al 1989; Furmaga et al 1993; Lakatta and
Levy 2003). The aged population frequently has co-morbid disease and limited
financial resources which may impact provider decision-making. Several studies
have compared the efficacy of antihypertensive agents in the elderly and therapeutic
recommendations based on these studies have been promulgated by different groups,
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most prominently by the 5th through 7th Joint National
Committees on the Detection, Evaluation, and Treatment
of High Blood Pressure (JNC 5–7) (JNC 1993, 1997;
Chobanian et al 2003). However, there is limited information
on existing patterns of antihypertensive treatment in the
elderly.
The present study was therefore undertaken to ascertain
the current patterns of antihypertensive therapy in an older
as compared with a younger population. We also desired to
compare patterns of antihypertensive therapy with
recommendations of national committees. For the timeframe
of this study, JNC 7 was not yet available and diuretics and
beta-blockers (BBs) were the recommended first-line agents
by JNC 5 and 6. Also, JNC 6 suggested caution in
prescribing either alpha-2 agonists (A2Ags), due to possible
resultant cognitive dysfunction, or drugs which “may
exaggerate postural changes in blood pressure” (eg, alpha-
1 blockers [A1Bs], peripheral adrenergic blockers, and high-
dose diuretics).
Methods
Study sample
The National Ambulatory Medical Care Survey (NAMCS)
is a survey of office-based physicians in the US which is
managed by the Center for Disease Control’s (CDCs)
National Center for Health Statistics. It has been conducted
annually since 1989. A report describing sample design,
sampling variation, and estimation procedures of the
NAMCS has been published (NCHS 1998). Non-federally
employed physicians from across the US are randomly
selected to participate in NAMCS. Physicians may not be
selected again for at least 3 years after inclusion in a given
year’s sample. Once selected, physicians’ patient encounters
are analyzed for a randomly assigned 7-day period of that
year. Physicians are asked to comment on various patient
characteristics (eg, sex, race, ethnicity) as well as list up to
3 diagnoses for the visit and up to 6 medications “ordered,
supplied, administered, or continued” during the visit. In
the NAMCS database, the diagnoses are noted according to
their ICD-9 codes and the medications have specific numeric
codes by which they are listed. Based on the geographic
and population data, each site center is designated as urban
or non-urban, and its region is designated as Northeast,
South, Midwest, or West.
We identified the encounters with an ICD-9 code for
essential hypertension (eg, 401.0, 401.1, or 401.9) in the
NAMCS database for the years 1995–2000. NAMCS data
sets were combined to produce reliable estimates regarding
medication usage of the essential hypertensive patient
population. We then analyzed the antihypertensive
medications listed for these encounters and classified them
into the appropriate therapeutic class. The antihypertensive
classes identified were A1Bs, A2Ags, angiotensin-
converting-enzyme inhibitors (ACEIs), angiotensin II
receptor blockers (ARBs), BBs, calcium-channel blockers,
both dihydropyridine and non-dihydropyridine (CCBs),
diuretics, and other (eg, rauwolfia). For combination
antihypertensives, we noted the patient was on both classes
of medications (eg, lotrel, which is a combination of
amlodipine and benazepril, was classified as both a CCB
and an ACEI).
Demographic data of the patient sample was also
obtained.
Data analysis
Descriptives
The hypertensive patient population (1995–2000) is
described by the estimated total patient visits, patient’s
gender, race (white, non-white), insurance type (self-pay,
all other), region’s population (metropolitan area, non-
metropolitan area), geographic location of region (Northeast,
Midwest, South, West) as they relate to age (less than 65
years, 65 years of age or older). Proportional comparisons
were made using the chi-square test of association. Since
the chi-square test determined unadjusted general
associations between geriatric age of patient and region,
pairwise comparisons were also performed to determine the
specific regional differences.
Mantel-Haenszel chi-square tests were performed to
determine the associations between geriatric age and the
demographic variables of gender, race, insurance type, urban
status, and region as stratified by survey year. The results
of the stratified analysis indicated similar associations
between geriatric age and the demographic variables. Within
each year strata, the association between geriatric age and
the demographic variables were the same.
Geriatric age
For the analysis, each antihypertensive class was
dichotomized into two categories, “medication prescribed”
and “medication not prescribed”. Bivariate analyses were
first performed to determine unadjusted associations
between antihypertensive class and geriatric age. For
antihypertensive medications that were statistically
associated with age 65 years and over (p≤0.05), multivariate
logistic regression analyses were performed to determineClinical Interventions in Aging 2006:1(3) 291
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adjusted associations between age (<65 years, ≥65 years)
and the prescription use of the antihypertensive classes. Each
analysis controlled for patient gender, race (white or non-
white), insurance type (self-pay, all other), urban status
(metropolitan area, non-metropolitan area), geographic
region (Northeast, Midwest, South, or West), and NAMCS
year (1995–2000).
Prescribing year trend
Prescribing time patterns of each antihypertensive
medication class were also explored. First, unadjusted chi-
squared analyses determined general associations between
year (1995–2000) and each of the antihypertensive
medication classes. For the antihypertensive medication
classes that were statistically associated with prescribing
year (p<0.05), an additional chi-square analysis was
performed. This analysis determined if the time trend
associations remained when the essential hypertensive
population was restricted by age (less than 65 years, 65 years
of age or older). These analyses were performed only for
hypertensive classes with sample sizes large enough to
produce reliable estimates according to National Center for
Health Statistics (NCHS) standards (number of sampled
patient visits is at least 30 and the relative standard error is
less than 0.30). Multivariate logistic regression analysis
determined adjusted association between antihypertensive
class and prescribing year while controlling for demographic
variables discussed above.
SAS-callable SUDAAN software was used to perform
each of the statistical procedures. Data were weighted, in
accordance with the statistical requirements of the NAMCS
database. Statistical associations were determined at the
alpha level of 0.05. All estimates reported are reliable by
NCHS standards.
Results
Descriptives
Per the NAMCS database, an estimated 332 510 280
essential hypertension patient visits occurred during 1995–
2000. The baseline characteristics of this group were
assessed (Table 1). Of these hypertensive patients, 51.3%
were 65 years of age or older. Hypertensive patients 65 years
and older were more likely female (63.8% vs 53.2% under
age 65; p<0.0001), white (83.2% vs 74.7% under age 65;
p<0.0001), insured (2.1% self-pay vs 7.7% self-pay under
age 65, p<0.0001) and reside in the Northeast region of the
US (23.5% vs 20.0% under age 65; p=0.0054).
Age analysis
Bivariate analyses determined unadjusted statistical
associations between the use of diuretics, CCBs, A1Bs,
A2Ags and hypertensive patients 65 years of age or older
(p<0.05). A higher proportion of elderly hypertensive
patients were prescribed or already taking these medications
when compared with younger hypertensive patients (Table
2).
Multivariate analyses determined adjusted associations
between the use of diuretics, CCBs, A1Bs, A2Ags, and age
category of hypertensive patients (p<0.05). Hypertensive
patients who were 65 years of age or older were more likely
to be prescribed or already using diuretics (adjusted odds
ratio [adj OR] – 65 yrs or older: 1.25, 95% confidence
interval [CI] [1.10, 1.41]), CCBs (adj OR – 65 yrs or older:
1.34, 95% CI [1.17, 1.53]), A1Bs (adj OR – 65 yrs or older:
1.66, 95% CI [1.23, 2.24]), or A2Ags (adj OR – 65 yrs or
older: 1.56, 95% CI [1.10, 2.23]) when compared with
essential hypertensive patients younger than 65 years of age
(Figure 1).
Table 1 Demographics of NAMCS database hypertensive patients between 1995–2000 (≥65 years vs <65 years)
Demographic <65 years SE ≥ ≥ ≥ ≥ ≥65 years SE p-value
# of Visits 162 066 279 8 783 013.7 170 444 001 8 955 696.8 0.0843
% Female 53.2 1.1 63.8 0.9 <0.0001
% Nonwhite 25.3 2.2 16.8 1.6 <0.0001
% Urban 19.4 3.2 21.7 3.5 0.1018
% Self-pay 7.7 0.6 2.1 0.4 <0.0001
Region overall        0.0425
% Northeast 20.0 1.8 23.5 2.1 0.0054
% South 25.4 2.0 25.2 2.1 0.8892
% Midwest 32.4 2.7 30.5 2.7 0.2216
% West 22.2 2.6 20.8 2.0 0.4374
Abbreviations: NAMCS, National Ambulatory Medical Care Survey; SE, standard error.
Note: 
“Region overall” refers to chi-square test of association. All other p-values indicate pairwise differences between geriatric age category for each region
category.Clinical Interventions in Aging 2006:1(3) 292
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Prescribing year trend
Bivariate analyses determined unadjusted statistical
associations between the usage of BBs and ARBs among
hypertensive patients and prescribing year, (p<0.05, data
not shown). The proportion of essential hypertensive patients
prescribed BBs appear to decrease between 1995 and 2000;
whereas the proportion of essential hypertensive patients
prescribed ARBs appear to increase. When the essential
hypertensive patient population was restricted to patients
65 years of age or older, there was no statistically significant
trend in the prescribing pattern of BBs over the same time
period (p=0.11). For ARBs, reliable estimates could not be
made due to the small number of ARB prescriptions in the
NAMCS essential hypertensive population aged 65 years
and older for this time period.
Discussion
Our results demonstrate that hypertensive patients aged 65
and over were treated differently than their younger
counterparts in the US from 1995–2000. Those over 65 years
of age were most commonly treated with diuretics, CCBs,
ACEIs, and BBs, in that order of prevalence. However, the
prescription of diuretics, CCBs, A1Bs, and A2Ags was
significantly more frequent in the older population than in
younger hypertensives. Our theories regarding this
discrepant prescribing are detailed below.
Diuretics and CCBs are recommended agents by JNC 6
in the hypertensive elderly population. Their preferential
use in the group aged 65 and older may reflect adherence to
evidence-based guidelines such as JNC 6. However, CCBs
were advocated by JNC 6 as second-line agents in the elderly
following diuretics and/or BBs. This study shows that CCBs
were preferentially prescribed more often than BBs to all
hypertensive patients, regardless of age. At best, physicians
were following the evidence in some ways (eg, by
prescribing diuretics frequently) while eschewing them in
others. Possibly, physician perceptions of frequent BB side
effects led to this behavior (Ubel et al 2003). Publicity for
CCBs by drug representatives may have led to more frequent
prescription for the general population, but this does not
explain their preferential use in the geriatric population.
Caution is urged in the prescription of A1Bs to the elderly
due to potential orthostatic hypotension, and yet these agents
were preferentially used in the elderly population. One can
surmise this is likely due to the frequent co-morbidity of
benign prostatic hyperplasia (BPH) in elderly men.
However, it is interesting to note that these medications were
specifically noted in a visit coded for hypertension, so some
practitioners may have considered these to be good
medications for high blood pressure in their elderly male
patients regardless of the degree of BPH which was present.
Subsequent to the timeframe we were studying, the
Antihypertensive and Lipid-lowering Treatment to Prevent
Heart Attack (ALLHAT) trial showed increased major
cardiovascular events in hypertensive patients treated with
an A1B versus a diuretic, and we now know that the A1B
medication class should be avoided for hypertension
indications alone (ALLHAT 2002).
A2Ags were also prescribed preferentially to the geriatric
population despite concerns that cognitive dysfunction,
notably sedation, may occur when used in this group (JNC
1997). We hypothesize that these medications were
prescribed years ago when there were few alternatives and
if they were well-tolerated, they were continued by
practitioners. We believe that the “grandfathering” of older
medications would result in a greater number of geriatric
patients on these medications than the younger hypertensive
population. Simply put, the longer that someone has been
hypertensive, the more likely they are taking an older
medication. Clearly, the geriatric population would be more
likely to have been hypertensive for a longer period of time
than younger adults. One other theory is that the convenience
Table 2 Unadjusted use of medications by NAMCS database hypertensive patients between 1995–2000 (≥65 years vs <65 years)
Medication usage <65 years (%) SE (%) ≥ ≥ ≥ ≥ ≥65 years (%) SE ($) p-value
Diur 24.9 0.9 30.1 1.1 0.0001
CCB 23 0.9 27.6 0.8 0.0005
ACEI 27.5 0.9 25.8 0.9 0.0910
BB 18.8 0.8 18.9 0.7 0.8878
A1B 3.9 0.6 5.4 0.5 0.0173
ARB 5.3 0.5 4.6 0.4 0.2099
A2Ag 2.2 0.3 3.1 0.3 0.0251
Other 0.8 0.2 1.1 0.2 0.2262
Abbreviations: A1B, alpha-1-blockers; A2Ag, alpha-2 agonists; ACEI, angiotensin-converting-enzyme inhibitor; ARB, angiotensin II receptor blocker; BB, beta-blocker;
CCB, calcium-channel blocker; Diur, diurectic; NAMCS, National Ambulatory Medical Care Survey; SE, standard error.Clinical Interventions in Aging 2006:1(3) 293
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of once-weekly topical dosing options with clonidine
patches leads to greater use in older adults who may suffer
from memory impairment or difficulties in swallowing pills.
There are several caveats to consider in reviewing our
results. Since the source of the data is dependent on multiple
doctors’ ICD-9 coding and the medications they chose to
list for the visit, the degree of completeness of the data is
uncertain. Patients who are hypertensive may not have been
included in the database search because the reason for that
visit was for a separate issue (eg, ankle sprain). Also, we do
not necessarily have a full medication list on our
hypertensive patients. The medications listed for each visit
in the NAMCS database may be those initiated and/or
continued. The discretion of the physician seeing the patient
dictated what was listed. Summing the prevalence of the
medications prescribed shows patients averaged just over
one medication in both elderly and younger adult categories.
If a newer medication was added to the prior regimen (eg,
CCB added to an existing regimen of BB and diuretic), we
could overestimate the relative prevalence of the newer
medications compared with the older agents. However, the
fact that diuretics were the leading medication listed for the
elderly population suggests this is not the case.
We have limited data on patients’ co-morbidities because
the physicians in NAMCS could only list up to 3 diagnoses
addressed in their patient encounter. This limits our ability
to evaluate the appropriateness of medications in patients
with “compelling indications”, per JNC 6. For example, if
we knew that many of the elderly patients on ACEIs had
diabetic nephropathy, there would be excellent evidence for
using that medication preferentially in that group. Likewise,
if we knew all of the elderly patients on A1Bs had
symptomatic BPH, then we would have a reasonable
explanation for its prescription.
Data are at least six years old in a rapidly changing field.
Although physician’s prescribing practices for hypertension
may have changed significantly in the interim, the significant
discrepancies between practice guidelines and physicians’
prescribing are still important to recognize. This suggests
additional efforts to promote adherence to JNC 7 may be
helpful in increasing the practice of evidence-based
medicine.
Sampling error is possible with the use of weighted data.
This is an inherent limitation of using the NAMCS database
as it must be weighted for proper interpretation. It is set up
to illustrate nationwide practices and individual patient
encounters must be weighted in order to achieve this. We
evaluated only the relatively healthy elderly population
which is seen in the ambulatory setting. However, we believe
this is appropriate for comparing the prescription of
antihypertensives in older and younger adult populations,
and for considering adherence with JNC 6.
Conclusions
The hypertensive population aged 65 and older was treated
with different medications than their younger counterparts
in the late 1990s. The increased usage of diuretics and CCBs
was evidence-based. However, the greater prevalence of
A1B and A2Ag prescription has potential for significant
adverse events in this group (JNC 1997; ALLHAT 2002).
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Figure 1 Adjusted odds ratio for hypertensive medication usage by NAMCS database hypertensive subjects between 1995–2000 (≥65 years vs <65 years old).
Abbreviations: A1B, alpha-1 blocker; A2Ag, alpha-2 agonist; ACEI, angiotensin-converting-enzyme inhibitor; ARB, angiotensin II receptor blocker; BB, beta-blocker;
CCB, calcium-channel blocker; CI, confidence interval; NAMCS, National Ambulatory Medical Care Survey; OR, odds ratio.Clinical Interventions in Aging 2006:1(3) 294
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BBs were under-prescribed in the hypertensive population
at large, likely due to exaggerated physician beliefs that they
are poorly tolerated (Ubel et al 2003). Physicians did not
adhere to the recommendations of the well-publicized
hypertension practice guidelines, JNC 5 and 6. This cross-
section of American physician antihypertensive prescribing
practices demonstrates the need for continued evidence-
based provider education.
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